Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05285566 · ClinicalTrials.gov registry record · Phase 4
Pain Control for Undergoing Costal Cartilage Harvesting
A Phase 4 study of Nasal Surgery, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05285566 is a Phase 4 study of Nasal Surgery that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05285566, a Phase 4 study of Nasal Surgery, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether injecting the U.S. Food and Drug Administration (FDA) approved drug EXPAREL®, a long acting (approximately 96 hours) numbing medication, will reduce pain after rib cartilage removal in comparison to the standard injection of XYLOCAINE®.
Conditions Studied
Interventions
- DRUG Exparel
- DRUG Xylocaine
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-05-04 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05285566
The ClinicalTrials.gov registry entry for NCT05285566 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nasal Surgery appearing as the primary indexed condition, and to 2 interventions - of which Exparel is the first listed.
NCT05285566 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05285566 about?
NCT05285566 is a clinical study titled "Pain Control for Undergoing Costal Cartilage Harvesting". The purpose of this study is to find out whether injecting the U.S. Food and Drug Administration (FDA) approved drug EXPAREL®, a long acting (approximately 96 hours) numbing medication, will reduce pain after rib cartilage removal in comparison to the standard injection of XYLOCAINE®.
What is the current status of trial NCT05285566?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2022-05-04. Estimated completion is 2026-09.
What conditions does trial NCT05285566 study?
This clinical trial studies the following conditions: Nasal Surgery.
What interventions are being tested in trial NCT05285566?
The interventions under investigation include: Exparel (DRUG), Xylocaine (DRUG).
Who is sponsoring clinical trial NCT05285566?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05285566 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.